0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global and United States Neurodegenerative Disease Market Size, Status and Forecast 2021-2027
Published Date: September 2021
|
Report Code: QYRE-Auto-16X6731
Home | Market Reports | Health | Health Foundations & Medical Research
Global and United States Neurodegenerative Disease Market Size Status and Forecast 2021 2027

Global and United States Neurodegenerative Disease Market Size, Status and Forecast 2021-2027

Code: QYRE-Auto-16X6731
Report
September 2021
123 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
Global Neurodegenerative Disease Scope and Market Size
Neurodegenerative Disease market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

NMDA
SSRIs
Dopamine Inhibitors

Segment by Application

Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease

BY REGION

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

BY COMPANY

Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Market by Application
1.3.1 Global Neurodegenerative Disease Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease Market Perspective (2016-2027)
2.2 Neurodegenerative Disease Growth Trends by Regions
2.2.1 Neurodegenerative Disease Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Disease Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Disease Industry Dynamic
2.3.1 Neurodegenerative Disease Market Trends
2.3.2 Neurodegenerative Disease Market Drivers
2.3.3 Neurodegenerative Disease Market Challenges
2.3.4 Neurodegenerative Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disease Players by Revenue
3.1.1 Global Top Neurodegenerative Disease Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disease Revenue
3.4 Global Neurodegenerative Disease Market Concentration Ratio
3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2020
3.5 Neurodegenerative Disease Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disease Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disease Breakdown Data by Type
4.1 Global Neurodegenerative Disease Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027)
5 Neurodegenerative Disease Breakdown Data by Application
5.1 Global Neurodegenerative Disease Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neurodegenerative Disease Market Size (2016-2027)
6.2 North America Neurodegenerative Disease Market Size by Type
6.2.1 North America Neurodegenerative Disease Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Disease Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Disease Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Disease Market Size by Application
6.3.1 North America Neurodegenerative Disease Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Disease Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Disease Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Disease Market Size by Country
6.4.1 North America Neurodegenerative Disease Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Disease Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Market Size (2016-2027)
7.2 Europe Neurodegenerative Disease Market Size by Type
7.2.1 Europe Neurodegenerative Disease Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Disease Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Disease Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Disease Market Size by Application
7.3.1 Europe Neurodegenerative Disease Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Disease Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Disease Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Disease Market Size by Country
7.4.1 Europe Neurodegenerative Disease Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Disease Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Disease Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Disease Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Disease Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size (2016-2027)
9.2 Latin America Neurodegenerative Disease Market Size by Type
9.2.1 Latin America Neurodegenerative Disease Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Disease Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Disease Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Disease Market Size by Application
9.3.1 Latin America Neurodegenerative Disease Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Disease Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Disease Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Disease Market Size by Country
9.4.1 Latin America Neurodegenerative Disease Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Disease Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Disease Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Disease Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Disease Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Neurodegenerative Disease Introduction
11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Disease Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Merck Serono
11.3.1 Merck Serono Company Details
11.3.2 Merck Serono Business Overview
11.3.3 Merck Serono Neurodegenerative Disease Introduction
11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021)
11.3.5 Merck Serono Recent Development
11.4 Biogen Idec
11.4.1 Biogen Idec Company Details
11.4.2 Biogen Idec Business Overview
11.4.3 Biogen Idec Neurodegenerative Disease Introduction
11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021)
11.4.5 Biogen Idec Recent Development
11.5 TEVA
11.5.1 TEVA Company Details
11.5.2 TEVA Business Overview
11.5.3 TEVA Neurodegenerative Disease Introduction
11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2016-2021)
11.5.5 TEVA Recent Development
11.6 UCB
11.6.1 UCB Company Details
11.6.2 UCB Business Overview
11.6.3 UCB Neurodegenerative Disease Introduction
11.6.4 UCB Revenue in Neurodegenerative Disease Business (2016-2021)
11.6.5 UCB Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction
11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021)
11.7.5 Boehringer Ingelheim Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neurodegenerative Disease Introduction
11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction
11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021)
11.9.5 GlaxoSmithKline Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Details
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction
11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.10.5 Livzon Pharmaceutical Recent Development
11.11 Haisco Pharmaceutical
11.11.1 Haisco Pharmaceutical Company Details
11.11.2 Haisco Pharmaceutical Business Overview
11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction
11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.11.5 Haisco Pharmaceutical Recent Development
11.12 Jingxin Pharmaceutical
11.12.1 Jingxin Pharmaceutical Company Details
11.12.2 Jingxin Pharmaceutical Business Overview
11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction
11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.12.5 Jingxin Pharmaceutical Recent Development
11.13 Dongcheng Biochemicals
11.13.1 Dongcheng Biochemicals Company Details
11.13.2 Dongcheng Biochemicals Business Overview
11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction
11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2016-2021)
11.13.5 Dongcheng Biochemicals Recent Development
11.14 Hisun Pharmaceutical
11.14.1 Hisun Pharmaceutical Company Details
11.14.2 Hisun Pharmaceutical Business Overview
11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction
11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.14.5 Hisun Pharmaceutical Recent Development
11.15 Luye Pharma
11.15.1 Luye Pharma Company Details
11.15.2 Luye Pharma Business Overview
11.15.3 Luye Pharma Neurodegenerative Disease Introduction
11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2016-2021)
11.15.5 Luye Pharma Recent Development
11.16 Ark Pharmaceutical
11.16.1 Ark Pharmaceutical Company Details
11.16.2 Ark Pharmaceutical Business Overview
11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction
11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.16.5 Ark Pharmaceutical Recent Development
11.17 Kanghong Pharmaceutical
11.17.1 Kanghong Pharmaceutical Company Details
11.17.2 Kanghong Pharmaceutical Business Overview
11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction
11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.17.5 Kanghong Pharmaceutical Recent Development
11.18 Huahai Pharmaceutical
11.18.1 Huahai Pharmaceutical Company Details
11.18.2 Huahai Pharmaceutical Business Overview
11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction
11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021)
11.18.5 Huahai Pharmaceutical Recent Development
11.18 BORA PHARMACEUTICALS
.1 BORA PHARMACEUTICALS Company Details
.2 BORA PHARMACEUTICALS Business Overview
.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction
.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2016-2021)
.5 BORA PHARMACEUTICALS Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of NMDA
    Table 3. Key Players of SSRIs
    Table 4. Key Players of Dopamine Inhibitors
    Table 5. Global Neurodegenerative Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Neurodegenerative Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Neurodegenerative Disease Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Neurodegenerative Disease Market Share by Regions (2016-2021)
    Table 9. Global Neurodegenerative Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
    Table 11. Neurodegenerative Disease Market Trends
    Table 12. Neurodegenerative Disease Market Drivers
    Table 13. Neurodegenerative Disease Market Challenges
    Table 14. Neurodegenerative Disease Market Restraints
    Table 15. Global Neurodegenerative Disease Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Neurodegenerative Disease Market Share by Players (2016-2021)
    Table 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020)
    Table 18. Ranking of Global Top Neurodegenerative Disease Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Neurodegenerative Disease Product Solution and Service
    Table 22. Date of Enter into Neurodegenerative Disease Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
    Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Neurodegenerative Disease Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Neurodegenerative Disease Revenue Market Share by Application (2016-2021)
    Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Neurodegenerative Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 37. North America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 38. Europe Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 43. Europe Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 44. Asia-Pacific Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Neurodegenerative Disease Market Size by Region (2016-2021) & (US$ Million)
    Table 49. Asia-Pacific Neurodegenerative Disease Market Size by Region (2022-2027) & (US$ Million)
    Table 50. Latin America Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 55. Latin America Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 56. Middle East & Africa Neurodegenerative Disease Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Neurodegenerative Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Neurodegenerative Disease Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Neurodegenerative Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Neurodegenerative Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 61. Middle East & Africa Neurodegenerative Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 62. Novartis Company Details
    Table 63. Novartis Business Overview
    Table 64. Novartis Neurodegenerative Disease Product
    Table 65. Novartis Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 66. Novartis Recent Development
    Table 67. Pfizer Company Details
    Table 68. Pfizer Business Overview
    Table 69. Pfizer Neurodegenerative Disease Product
    Table 70. Pfizer Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 71. Pfizer Recent Development
    Table 72. Merck Serono Company Details
    Table 73. Merck Serono Business Overview
    Table 74. Merck Serono Neurodegenerative Disease Product
    Table 75. Merck Serono Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 76. Merck Serono Recent Development
    Table 77. Biogen Idec Company Details
    Table 78. Biogen Idec Business Overview
    Table 79. Biogen Idec Neurodegenerative Disease Product
    Table 80. Biogen Idec Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 81. Biogen Idec Recent Development
    Table 82. TEVA Company Details
    Table 83. TEVA Business Overview
    Table 84. TEVA Neurodegenerative Disease Product
    Table 85. TEVA Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 86. TEVA Recent Development
    Table 87. UCB Company Details
    Table 88. UCB Business Overview
    Table 89. UCB Neurodegenerative Disease Product
    Table 90. UCB Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 91. UCB Recent Development
    Table 92. Boehringer Ingelheim Company Details
    Table 93. Boehringer Ingelheim Business Overview
    Table 94. Boehringer Ingelheim Neurodegenerative Disease Product
    Table 95. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 96. Boehringer Ingelheim Recent Development
    Table 97. Sanofi Company Details
    Table 98. Sanofi Business Overview
    Table 99. Sanofi Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 100. Sanofi Recent Development
    Table 101. GlaxoSmithKline Company Details
    Table 102. GlaxoSmithKline Business Overview
    Table 103. GlaxoSmithKline Neurodegenerative Disease Product
    Table 104. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 105. GlaxoSmithKline Recent Development
    Table 106. Livzon Pharmaceutical Company Details
    Table 107. Livzon Pharmaceutical Business Overview
    Table 108. Livzon Pharmaceutical Neurodegenerative Disease Product
    Table 109. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 110. Livzon Pharmaceutical Recent Development
    Table 111. Haisco Pharmaceutical Company Details
    Table 112. Haisco Pharmaceutical Business Overview
    Table 113. Haisco Pharmaceutical Neurodegenerative Disease Product
    Table 114. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 115. Haisco Pharmaceutical Recent Development
    Table 116. Jingxin Pharmaceutical Company Details
    Table 117. Jingxin Pharmaceutical Business Overview
    Table 118. Jingxin Pharmaceutical Neurodegenerative Disease Product
    Table 119. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 120. Jingxin Pharmaceutical Recent Development
    Table 121. Dongcheng Biochemicals Company Details
    Table 122. Dongcheng Biochemicals Business Overview
    Table 123. Dongcheng Biochemicals Neurodegenerative Disease Product
    Table 124. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 125. Dongcheng Biochemicals Recent Development
    Table 126. Hisun Pharmaceutical Company Details
    Table 127. Hisun Pharmaceutical Business Overview
    Table 128. Hisun Pharmaceutical Neurodegenerative Disease Product
    Table 129. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 130. Hisun Pharmaceutical Recent Development
    Table 131. Luye Pharma Company Details
    Table 132. Luye Pharma Business Overview
    Table 133. Luye Pharma Neurodegenerative Disease Product
    Table 134. Luye Pharma Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 135. Luye Pharma Recent Development
    Table 136. Ark Pharmaceutical Company Details
    Table 137. Ark Pharmaceutical Business Overview
    Table 138. Ark Pharmaceutical Neurodegenerative Disease Product
    Table 139. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 140. Ark Pharmaceutical Recent Development
    Table 141. Kanghong Pharmaceutical Company Details
    Table 142. Kanghong Pharmaceutical Business Overview
    Table 143. Kanghong Pharmaceutical Neurodegenerative Disease Product
    Table 144. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 145. Kanghong Pharmaceutical Recent Development
    Table 146. Huahai Pharmaceutical Company Details
    Table 147. Huahai Pharmaceutical Business Overview
    Table 148. Huahai Pharmaceutical Neurodegenerative Disease Product
    Table 149. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 150. Huahai Pharmaceutical Recent Development
    Table 151. BORA PHARMACEUTICALS Company Details
    Table 152. BORA PHARMACEUTICALS Business Overview
    Table 153. BORA PHARMACEUTICALS Neurodegenerative Disease Product
    Table 154. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2016-2021) & (US$ Million)
    Table 155. BORA PHARMACEUTICALS Recent Development
    Table 156. Research Programs/Design for This Report
    Table 157. Key Data Information from Secondary Sources
    Table 158. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurodegenerative Disease Market Share by Type: 2020 VS 2027
    Figure 2. NMDA Features
    Figure 3. SSRIs Features
    Figure 4. Dopamine Inhibitors Features
    Figure 5. Global Neurodegenerative Disease Market Share by Application: 2020 VS 2027
    Figure 6. Parkinson’s Disease Case Studies
    Figure 7. Huntington Disease Case Studies
    Figure 8. Amyotrophic Lateral Sclerosis Case Studies
    Figure 9. Alzheimer’s Disease Case Studies
    Figure 10. Neurodegenerative Disease Report Years Considered
    Figure 11. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Neurodegenerative Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Neurodegenerative Disease Market Share by Regions: 2020 VS 2027
    Figure 14. Global Neurodegenerative Disease Market Share by Regions (2022-2027)
    Figure 15. Global Neurodegenerative Disease Market Share by Players in 2020
    Figure 16. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Disease as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2020
    Figure 18. Global Neurodegenerative Disease Revenue Market Share by Type (2016-2021)
    Figure 19. Global Neurodegenerative Disease Revenue Market Share by Type (2022-2027)
    Figure 20. North America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Neurodegenerative Disease Market Share by Type (2016-2027)
    Figure 22. North America Neurodegenerative Disease Market Share by Application (2016-2027)
    Figure 23. North America Neurodegenerative Disease Market Share by Country (2016-2027)
    Figure 24. United States Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Neurodegenerative Disease Market Share by Type (2016-2027)
    Figure 28. Europe Neurodegenerative Disease Market Share by Application (2016-2027)
    Figure 29. Europe Neurodegenerative Disease Market Share by Country (2016-2027)
    Figure 30. Germany Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Neurodegenerative Disease Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Neurodegenerative Disease Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Neurodegenerative Disease Market Share by Region (2016-2027)
    Figure 40. China Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Neurodegenerative Disease Market Share by Type (2016-2027)
    Figure 48. Latin America Neurodegenerative Disease Market Share by Application (2016-2027)
    Figure 49. Latin America Neurodegenerative Disease Market Share by Country (2016-2027)
    Figure 50. Mexico Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Neurodegenerative Disease Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Neurodegenerative Disease Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Neurodegenerative Disease Market Share by Country (2016-2027)
    Figure 56. Turkey Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Neurodegenerative Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 60. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 61. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 62. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 63. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 64. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 65. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 66. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 67. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 68. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 69. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 70. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 71. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 72. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 73. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 74. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 75. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 76. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 77. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2016-2021)
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3900
This license allows only one user to access the PDF.

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Accenture

RELATED REPORTS

China Artificial Blood Substitute Market Report Forecast 2021 2027
China Artificial Blood Substitute Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-31R5313
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Myasthenia Gravis Market Size Status and Forecast 2021 2027
Global and United States Myasthenia Gravis Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-28J3997
Thu Sep 23 00:00:00 UTC 2021

Add to Cart

Global and China Stem Cell Cryopreservation Equipment Market Insights Forecast to 2027
Global and China Stem Cell Cryopreservation Equipment Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-11M6930
Tue Sep 21 00:00:00 UTC 2021

Add to Cart